ProCE Banner Activity

BTK Inhibitor Therapy for CLL: An International Perspective

Clinical Thought

In this commentary, an international expert discusses contemporary use of BTK inhibitor therapy for CLL.

Released: March 28, 2023

Expiration: March 27, 2024

Share

Faculty

Stephan Stilgenbauer

Stephan Stilgenbauer, MD

Prof. Dr. Med. Stephan Stilgenbauer

Medical Director Comprehensive Cancer Center Ulm (CCCU)

Head Early Clinical Trials Unit (ECTU)

Head Division of CLL Department of Internal Medicine III

Ulm University

Ulm, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Faculty Disclosure

Stephan Stilgenbauer: consultant/advisor/speaker: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem; researcher: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem.